Observed Signal · Nov 9, 2026 · executive_change · Source: SEC API · Impact: 3.8/5
Hims & Hers Appoints Dr. Andrew Huberman to Board and Enters Multi-Million Dollar Marketing Agreements
On November 4, 2026, Hims & Hers Health, Inc. expanded its Board of Directors from nine to ten members and appointed Dr. Andrew Huberman as a director, serving until the 2027 annual meeting. The Board determined Dr. Huberman is not independent under NYSE listing standards and he will not serve on any Board committees. Alongside standard director compensation ($50,000 cash retainer and $250,000 prorated equity), the company entered into substantial related-party commercial arrangements with Dr. Huberman and his affiliate on November 5, 2026. Specifically, subsidiary Hims, Inc. entered into a two-year brand marketing and advisory agreement with Dr. Huberman for an annual cash fee of $3.5 million, plus up to $1.0 million annually for short-form video creation. Additionally, Hims signed a three-year marketing agreement with Scicomm Media LLC, co-owned by Dr. Huberman, for podcast advertising services at $5.0 million annually (with Dr. Huberman's annual interest valued at approximately $2.1 million).
While an Item 5.02 director appointment is standard corporate governance, the simultaneous execution of up to $9.5 million in annual commercial marketing and advisory commitments with a non-independent director represents a material related-party transaction and a major influencer-driven brand marketing deployment.
MARKET SIGNALS
Track Hims & Hers Signals & Strategic Shifts
Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.
- Verified primary sources
- Automated briefings
- Instant watchlist setup
Key Takeaways & Evidence Grounding
- Dr. Andrew Huberman appointed to the Board of Directors, expanding board size from 9 to 10; determined non-independent under NYSE rules.
- Director compensation set at a $50,000 annual cash retainer and a $250,000 annual equity award prorated through the 2027 annual meeting.
- Hims entered into a two-year advisory agreement with Dr. Huberman providing $3.5M annually in cash plus up to $1.0M annually for short-form video ads.
- Hims entered into a three-year podcast marketing agreement with Huberman's Scicomm Media LLC for $5.0M annually ($2.1M annual interest to Huberman).
Connected Companies & Entities
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
8-K Financial Filing Analysis for Hims & Hers (2026-10-07)
Hims & Hers Health, Inc. announced the appointment of Jonathan M. Franklin as Chief Accounting Officer and Principal Accounting Officer, effective October 9, 2026. Mr. Franklin succeeds Irene Becklund, who previously resigned but will remain with the company in an advisory capacity through July 10, 2027, ensuring an orderly transition. Prior to joining Hims & Hers, Franklin served as Vice President, Corporate Controller at Rivian Automotive and spent over 15 years in public accounting at PwC. His compensation package includes an annual base salary of $425,000, a $150,000 signing bonus, an annual target bonus of 50%, and an initial grant of $3,000,000 in restricted stock units (RSUs) vesting over four years.
Hims & Hers Securities Class Action Deadline Nov 2, 2026
Robbins Geller Rudman & Dowd LLP has announced a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS), alleging violations of the Securities Exchange Act. The lawsuit, captioned Velanki v. Hims & Hers Health, Inc., is pending in the Northern District of California. It claims that the company made false statements and failed to disclose that it shared consumers' sensitive health information with third-party advertising platforms like Meta and Snap, and that it misled consumers about billing practices. Following an FTC lawsuit filed on July 29, 2026, the company's stock dropped nearly 15%. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026, to seek lead plaintiff appointment under the Private Securities Litigation Reform Act.
Hims & Hers Securities Fraud Class Action Filed
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) in the U.S. District Court for the Northern District of California. The suit alleges the telehealth company disclosed sensitive health information to third-party advertising platforms, including Snap and Meta (Facebook), without proper consent, and misled consumers about billing practices. The FTC filed a related lawsuit on July 29, 2026, causing the stock to drop 14.73% to $25.00. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to apply as lead plaintiff. The case, Velanki v. Hims & Hers Health, Inc. et al., is being publicized by law firms including Kahn Swick & Foti, Kessler Topaz Meltzer & Check, and the Law Offices of Howard G. Smith.
WATCHLIST & BRIEFINGS
Receive future signals for Hims & Hers & competitors in your briefing
Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.
- Regular primary-source checks
- Structured Watchlist briefings
- Preserves current context
Market Signal Monitoring
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
Monitor Hims & Hers
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
